MOMA Therapeutics
Organization
Trials
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Phase 1, Recruiting, 132 people, May 15, 2025
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Phase 1, Recruiting, 220 people, Aug 9, 2024
Sources: clinicaltrials.gov
Named in competing interests
Consulting or advice, Grants or research support, Sep 6, 2026
Sources: pubmed.ncbi.nlm.nih.gov